Perampanel for Post-Cardiac Arrest Seizures
(PROSPER Trial)
Trial Summary
What is the purpose of this trial?
Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug Perampanel (Fycompa) for post-cardiac arrest seizures?
Perampanel (Fycompa) is effective in controlling seizures in people with epilepsy, particularly focal-onset seizures and generalized tonic-clonic seizures, as shown in various studies. While these studies focus on epilepsy, the drug's ability to manage seizures in these conditions suggests it might also help with post-cardiac arrest seizures.12345
Is Perampanel safe for humans?
How is the drug Perampanel unique for treating post-cardiac arrest seizures?
Perampanel is unique because it works by blocking glutamate receptors in the brain, which is different from many other seizure medications that target different pathways. This mechanism may offer a novel approach for managing seizures after cardiac arrest, where standard treatments are not well-established.12468
Research Team
Edilberto Amorim, MD
Principal Investigator
University of California, San Francisco
Eligibility Criteria
This trial is for patients who have survived a cardiac arrest but are at risk of developing seizures due to brain injury. It's not specified who can't join, so it's important to consult with the study team for exclusion criteria.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either perampanel or placebo for post-cardiac arrest status epilepticus prevention
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Neurological function assessed at 180 days post-treatment
Treatment Details
Interventions
- Perampanel
Perampanel is already approved in European Union, United States for the following indications:
- Partial-onset epilepsy (with or without secondary generalized seizures)
- Primary generalized tonic-clonic seizures
- Partial-onset seizures (with or without secondary generalized seizures)
- Primary generalized tonic-clonic seizures
- Monotherapy and adjunctive therapy for focal epilepsy (with or without secondary generalized seizures) in patients aged 4 years and older
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of California, San Francisco
Lead Sponsor